Motus GI (NASDAQ:MOTS) & Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review

Motus GI (NASDAQ:MOTS) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Motus GI and Minerva Surgical’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$320,000.00	0.92	-$12.87 million	($15.64)	0.00
Minerva Surgical	$50.29 million	0.00	-$34.11 million	($8.21)	0.00

Motus GI has higher earnings, but lower revenue than Minerva Surgical. Motus GI is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Motus GI and Minerva Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	-3,239.75%	-1,731.08%	-115.99%
Minerva Surgical	N/A	N/A	N/A

Institutional & Insider Ownership

20.1% of Motus GI shares are owned by institutional investors. 0.3% of Motus GI shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Motus GI and Minerva Surgical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Motus GI	0	0	1	0	3.00
Minerva Surgical	0	0	0	0	N/A

Motus GI presently has a consensus price target of $28.88, suggesting a potential upside of 56,517.65%. Given Motus GI’s higher possible upside, equities analysts clearly believe Motus GI is more favorable than Minerva Surgical.

Volatility & Risk

Motus GI has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 4.67, indicating that its share price is 367% more volatile than the S&P 500.

Summary

Minerva Surgical beats Motus GI on 7 of the 12 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.